Atomoxetine-d7

Atomoxetine-d7 (Tomoxetine-d7) is deuterium labeled Atomoxetine. Atomoxetine (Tomoxetine) is a selective noradrenaline reuptake inhibitor with Ki values of 5, 77 and 1451 nM for norepinephrine (NE), serotonin (5-HT) and dopamine (DA) transporters, respectively. Atomoxetine (Tomoxetine) increases of DAEX and NEEX in the PFC and enhances catecholaminergic neurotransmission. Atomoxetine (Tomoxetine) is a potent Na+ channels (VGSCs) blocker. Atomoxetine (Tomoxetine) can be used for attention-deficit hyperactivity disorder (ADHD) research[1][2][3].

Product Specifications

CAS Number

[919104-07-7]

Product Name Alternative

Tomoxetine-d7; (R) -Tomoxetine-d7

UNSPSC

12352005

Target

Isotope-Labeled Compounds; Serotonin Transporter; Sodium Channel

Related Pathways

Membrane Transporter/Ion Channel; Neuronal Signaling; Others

Applications

Cancer-programmed cell death

Field of Research

Neurological Disease; Cancer

Smiles

[2H]C([2H])([2H])C(C([2H])=C([2H])C([2H])=C1[2H])=C1O[C@@H](C2=CC=CC=C2)CCNC

Molecular Formula

C17H14D7NO

Molecular Weight

262.40

References & Citations

[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-216.|[2]Turner M, et, al. Effects of atomoxetine on locomotor activity and impulsivity in the spontaneously hypertensive rat. Behav Brain Res. 2013 Apr 15;243:28-37. |[3]Föhr KJ, et, al. Block of Voltage-Gated Sodium Channels by Atomoxetine in a State- and Use-dependent Manner. Front Pharmacol. 2021 Feb 25;12:622489.|[4]Bymaster FP, et, al. Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: a potential mechanism for efficacy in attention deficit/hyperactivity disorder. Neuropsychopharmacology. 2002 Nov;27 (5) :699-711.